TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18772269

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Combined dietary and exercise intervention
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (dietary only)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (exercise only)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (dietary and exercise)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Increased exercise
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Increased fiber intake
Number of subjects: 335
Study: 16999056

Group type: EXPERIMENTAL
Intervention: Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) twice daily
Number of subjects: 2482
Study: 12580651

Group type: EXPERIMENTAL
Intervention: Gatorlode (CHO)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 7
Study: 10691221

Group type: EXPERIMENTAL
Intervention: BFCN (bupivacaine 2.5 mg, fentanyl 25 microg, clonidine 30 microg, neostigmine 10 microg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: BF (bupivacaine 2.5 mg, fentanyl 25 microg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: BFC (bupivacaine 2.5 mg, fentanyl 25 microg, clonidine 30 microg)
Number of subjects: 45
Study: 7855199

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.3% and 0.6%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (20% and 40%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isoflurane (0.0%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrous oxide (0%)
Number of subjects: 9
Study: 2595800

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 138

Group type: COMPARATOR
Intervention: 5% glucose solution
Number of subjects: 138
Study: 1092729

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31642953

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 31502297

Group type: EXPERIMENTAL
Intervention: Personalized chance of longer survival measure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hazard ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonparametric estimation and inference procedures
Number of subjects: 0
Study: 28285751

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.06 mg/kg daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 25436620

Group type: EXPERIMENTAL
Intervention: 5 sets of 8‐10 repetitions at 70% 1RM
Number of subjects: 11

Group type: COMPARATOR
Intervention: 1 set of 8‐10 repetitions at 70% 1RM
Number of subjects: 11

Group type: COMPARATOR
Intervention: 3 sets of 8‐10 repetitions at 70% 1RM
Number of subjects: 11
Study: 24872136

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 170

Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 170
Study: 21748366

Group type: EXPERIMENTAL
Intervention: Testosterone (T) only at 5 or 10 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone (T) + recombinant human growth hormone (rhGH) at 0, 3.0 or 5.0 μg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entire cohort, T only, and T + rhGH groups
Number of subjects: 0
Study: 18978489

Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17900228

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 19
Study: 15057253

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 86
Study: 11575407

Group type: EXPERIMENTAL
Intervention: Propofol (4‐6 mg kg(‐1) h(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC)
Number of subjects: 40
Study: 9613540

Group type: EXPERIMENTAL
Intervention: Repetitive intercostal blocks (10-20 mL 0.5% bupivacaine, 2-4 times per day for 3-6 days; n = 17)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Interpleural injections via a catheter (20 mL 0.25%, 4-6 times per day for 3-6 days; n = 25 for right, n = 12 for left)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 50 mL 0.125% bupivacaine (n = 18)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 50 mL 0.25% bupivacaine (n = 20)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (systemic analgesia only: patient‐controlled analgesia with opioids; n = 26)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 50 mL saline (Control; n = 21)
Number of subjects: 126
Study: 7627864

Group type: EXPERIMENTAL
Intervention: Duodenal drainage during saline infusion
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Duodenal drainage during mannitol infusion
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Non-drainage during saline infusion
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Non-drainage during mannitol infusion
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group during first 4-h session
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group during second session
Number of subjects: 3
Study: 2035049

Group type: EXPERIMENTAL
Intervention: Paper/pencil format
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Computer format
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnitude estimation method
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Linear analogue scaling method
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Context effects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interviewers
Number of subjects: 100
Study: 6111295

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (antihistamine H1-antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no clemastine treatment)
Number of subjects: 0
Study: 30720587

Group type: EXPERIMENTAL
Intervention: Early integrated ART during TB treatment
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Early integrated ART during TB treatment (adjusted for noncompliance)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Overall effect of ART exposure (time-varying IV analysis)
Number of subjects: 642
Study: 29035677

Group type: EXPERIMENTAL
Intervention: Smartphone intervention using the Noom app for weight loss (15 weeks)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Smartphone intervention using the Noom app for weight loss (52 weeks follow-up)
Number of subjects: 104
Study: 25805628

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control intervention (B)
Number of subjects: 12
Study: 24220376

Group type: EXPERIMENTAL
Intervention: Merocel nasal tampon within glove finger moistened with tetracaine 0.25% solution, removed after 24 hours
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Merocel nasal tampon within glove finger moistened with tetracaine 0.25% solution, removed after 48 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Merocel nasal tampon removed after 24 hours
Number of subjects: 80
Study: 21883127

Group type: EXPERIMENTAL
Intervention: Early group (100 patients)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Late group (100 patients)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (100 patients)
Number of subjects: 200
Study: 19793371

Group type: EXPERIMENTAL
Intervention: Free right atrial wall (A)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Right atrial appendage (B)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Coronary sinus ostium (C)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Dual site right atrial pacing (CS‐Os + RAA) (D)
Number of subjects: 142
Study: 17767166

Group type: EXPERIMENTAL
Intervention: LY2140023
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15282385

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 200 micro g + formoterol (FM) 6 micro g (two puffs twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 250 micro g + salmeterol (SM) 50 micro g (one puff twice daily)
Number of subjects: 20
Study: 11147897

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (34 degrees C) for 48 hours, followed by rewarming at 1 degrees C per day for 3 days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C) for 5 days
Number of subjects: 91
Study: 9769262

Group type: EXPERIMENTAL
Intervention: RTCS-directed respiratory care
Number of subjects: 145

Group type: COMPARATOR
Intervention: Physician-directed respiratory care
Number of subjects: 145
Study: 7987868

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 2847687

Group type: EXPERIMENTAL
Intervention: Live, attenuated cytomegalovirus (CMV) vaccination (Towne strain)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 29879369

Group type: EXPERIMENTAL
Intervention: New Zealand Secretion Scale (NZSS) scored by experts
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: New Zealand Secretion Scale (NZSS) scored by untrained raters
Number of subjects: 28
Study: 29178725

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash with anti-discoloration system (CHX+ADS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash without anti-discoloration system (CHX)
Number of subjects: 22
Study: 25777831

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (IV tPA) + Solitaire revascularization device
Number of subjects: 833

Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator (IV tPA) alone
Number of subjects: 833
Study: 23740224

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 404

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Combined endpoint (Dabigatran + Warfarin)
Number of subjects: 404
Study: 21359209

Group type: EXPERIMENTAL
Intervention: Self-face recognition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perceived social status of the boss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Boss's face presented with a labmate's face
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cultural differences in self-processing
Number of subjects: 20
Study: 18317244

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 0
Study: 16988120

Group type: EXPERIMENTAL
Intervention: 1 egg per day for 5 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Egg substitute per day for 5 weeks
Number of subjects: 33
Study: 14673683

Group type: EXPERIMENTAL
Intervention: Th2‐3 ETS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Th2‐4 ETS
Number of subjects: 25
Study: 10731537

Group type: EXPERIMENTAL
Intervention: IUI and FT-ET with ovulation induction (Clomiphene citrate and hCG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: FT-ET with ovulation induction (Clomiphene citrate and hCG)
Number of subjects: 62
Study: 9187886

Group type: EXPERIMENTAL
Intervention: Aflurax 1200 mg, two tablets four times daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 8237844

Group type: COMPARATOR
Intervention: Whole cow milk plus iron-fortified cereal (WCM + C)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Iron-fortified follow-up formulas
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Iron-fortified infant formula
Number of subjects: 104
Study: 3888886

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lactose (Control)
Number of subjects: 18
Study: 31539086

Group type: EXPERIMENTAL
Intervention: Self-directed learning digital tool
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tutorials under the guidance of an educator
Number of subjects: 27
Study: 29554032

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 26716734

Group type: EXPERIMENTAL
Intervention: Focused-Breathing Strategy (FBS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Focused-Distraction Strategy (FDS)
Number of subjects: 82
Study: 24651151

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection of the Rectus Femoris (RF) muscle
Number of subjects: 14
Study: 22222102

Group type: EXPERIMENTAL
Intervention: Peak flow monitoring during a 16-week asthma self-management program
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Peak flow monitoring
Number of subjects: 77
Study: 20299336

Group type: EXPERIMENTAL
Intervention: Usual exposure to cyclosporine (n = 101)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Low exposure to cyclosporine (n = 106)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Usual exposure to cyclosporine
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Low exposure to cyclosporine
Number of subjects: 212
Study: 17998023

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg taken twice a day for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15824911

Group type: EXPERIMENTAL
Intervention: Ciclesonide via hydrofluoroalkane metered-dose inhaler
Number of subjects: 18

Group type: COMPARATOR
Intervention: Budesonide via chlorofluorocarbon metered-dose inhaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Des-CIC
Number of subjects: 18
Study: 12496745

Group type: EXPERIMENTAL
Intervention: Irinotecan (100-340 mg/m²)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SN-38 and SN-38 glucuronide (SN-38G)
Number of subjects: 78
Study: 9800929

Group type: EXPERIMENTAL
Intervention: Uterine exteriorisation
Number of subjects: 194

Group type: COMPARATOR
Intervention: In situ repair
Number of subjects: 194
Study: 8587687

Group type: EXPERIMENTAL
Intervention: Microsurgical resection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Microsurgical resection with preoperative transfemoral embolization
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Radiosurgery for residual AVMs
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Embolization followed by radiosurgery for surgically inaccessible AVMs
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall treatment approach
Number of subjects: 32
Study: 2501104

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and sodium cromoglycate
Number of subjects: 10
Study: 29444707

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 184
Study: 26516142

Group type: EXPERIMENTAL
Intervention: Chronic statin therapy
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Adjuvanted and unadjuvanted vaccine groups
Number of subjects: 5000
Study: 24810369

Group type: EXPERIMENTAL
Intervention: elosulfase alfa 2.0 mg/kg/week
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: elosulfase alfa 2.0 mg/kg/every other week (qow)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 23573238

Group type: EXPERIMENTAL
Intervention: Reduced glycerin formulation of tenofovir 1% gel
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl cellulose placebo gel
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nonoxynol‐9 gel
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fecal calprotectin, rectal microflora, and epithelial sloughing
Number of subjects: 65

Group type: COMPARATOR
Intervention: Histology, mucosal gene expression, protein expression, and T cell phenotype
Number of subjects: 65
Study: 30148449

Group type: EXPERIMENTAL
Intervention: 4% sodium citrate
Number of subjects: 210

Group type: COMPARATOR
Intervention: Heparin 5,000 µ/mL
Number of subjects: 210
Study: 18444147

Group type: EXPERIMENTAL
Intervention: 8 servings/day of vegetables and fruit (VF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2 servings/day of vegetables and fruit (VF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 5 servings/day of vegetables and fruit (VF)
Number of subjects: 64
Study: 16540291

Group type: EXPERIMENTAL
Intervention: Delusional patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-delusional patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 3
Study: 14517193

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) 3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) 9 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) 18 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) 36 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) with high-fat breakfast (9 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) with high-fat breakfast (36 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10863679

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills training (CBST) treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined (biofeedback/CBST) treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 94
Study: 9483717

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segments influenced by PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Segments not influenced by PTCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segments influenced by CABG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Segments not influenced by CABG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Existing lesions proximal to bypass anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing lesions not proximal to bypass anastomosis
Number of subjects: 0
Study: 1440167

Group type: COMPARATOR
Intervention: Single drain (one catheter in the axilla and one catheter under the inferior flap for modified radical mastectomy)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Multiple drains (four catheters in the axilla for axillary dissection; four catheters in the axilla and one under the inferior flap for modified radical mastectomy)
Number of subjects: 65
Study: 3515927

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Codeine (60 or 120 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 31712969

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 2400 mg daily for 12 weeks
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 302
Study: 29734488

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 108
Study: 29901322

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (Staest) intake
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (Staest) intake with meal
Number of subjects: 113

Group type: COMPARATOR
Intervention: Other mutations (control group)
Number of subjects: 113
Study: 24901900

Group type: EXPERIMENTAL
Intervention: Bite Back (n=120)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control websites (n=115)
Number of subjects: 235
Study: 22429760

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once a day (OaD)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Tadalafil 20 mg as needed (PRN)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Sildenafil 100 mg as needed (PRN)
Number of subjects: 378
Study: 20411444

Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask airway (SLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proseal laryngeal mask airway (PLMA)
Number of subjects: 60
Study: 18339360

Group type: EXPERIMENTAL
Intervention: TPA023B (1.5 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 16793612

Group type: EXPERIMENTAL
Intervention: ANH (Acute Normovolemic Hemodilution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ANH combined with controlled hypotension
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (routine blood transfusion and fluid infusion)
Number of subjects: 30
Study: 12735161

Group type: EXPERIMENTAL
Intervention: Triamcinolone/bupivacaine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 21
Study: 10669060

Group type: EXPERIMENTAL
Intervention: Progressive increase in magnitude of reinforcement for abstinence with a reset contingency for drug use
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fixed magnitude of reinforcement for abstinence
Number of subjects: 18

Group type: COMPARATOR
Intervention: Progressive increase in magnitude of reinforcement for abstinence without a reset contingency
Number of subjects: 18
Study: 9191764

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneous)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19